GENOMICS---STRENGTHS AND LIMITATIONS {#s1}
====================================

Deep sequencing technology has changed the face of nearly every area of biological research and has led to a number of breakthroughs in clinical medicine ([@TYNERMCS001370C23]). As a result, the concept of personalized medicine that is driven by genomic analysis has become pervasive. Although genomically guided precision medicine is a very powerful concept, its implementation is impeded by a lack of biological understanding of the pharmacological ramifications of most tumor-associated genetic lesions. In addition, the combinatorial complexity of tumor genetics further complicates the assignment of drugs to mutational events.

One illustration of this point comes from hematologic malignancies and the elegant work to decipher the genetic etiology of some of these diseases such as acute myeloid leukemia (AML) ([@TYNERMCS001370C49]). A small number of the genetic lesions found in AML are targetable, including mutations or fusions involving signaling proteins (e.g., kinases such as FLT3, KIT) and metabolic pathways (e.g., IDH1/2). However, the majority of genetic events observed in AML (as well as most other malignancies) do not fall within this class of genes but in alternative gene families such as those that play a role in regulating epigenetic processes or transcriptional splicing. Some of these mutational events may eventually be directly targetable through drug discovery efforts; however, many of the mutations result in loss of function of the mutated protein. Consequently, drug targeting strategies must focus on biological events downstream from these loss-of-function mutations, and our understanding of most of these downstream events is not sufficiently mature to predict actionable drug targets.

This dilemma is not confined to AML or even to hematologic malignancies, but is a common issue in solid tumors as well, where currently targetable lesions are often confined to kinase point mutations (e.g., BRAF), kinase fusions (e.g., ALK fusions), and some of the very same metabolic pathway lesions (IDH1/2). In addition, many types of solid tumors exhibit significantly higher mutational burden rates, adding to the challenges of assigning the best drugs to patients on the basis of a complex genetic profile. In addition to the knowledge gap preventing easy clinical translation of many genetic events, there are also some technical limitations to current sequencing approaches. The short-read technology now favored by most laboratories results in limited capacity to detect chromosomal breaks and rearrangements as well as copy-number variation, both issues that may ultimately be ameliorated with long-read sequencing technology. In addition, although sequencing is broadly applicable to many tumors and tumor types, there is a subset of cases where sequencing is infeasible because of low quantity/quality of tissue (e.g., formalin-fixed, paraffin-embedded), low tumor burden, and extreme heterogeneity of the tumor cells.

In recent years, many new functional screening strategies have emerged that aim to assess the impact of exogenous interventions such as drug exposure on tumor cell phenotype. These functional screening platforms deliver information regarding the capacity of drugs to elicit apoptotic responses of cancer cells without a priori knowledge of the mechanistic underpinnings of such responses. As such, these tools represent a tremendous opportunity to synergize with genomic data, where functional drug sensitivity can offer alignment of actionable strategies with mutational status and genomic data can help elucidate the etiologies of observed drug sensitivity patterns ([Fig. 1](#TYNERMCS001370F1){ref-type="fig"}).

![Functional genomics can accelerate elucidation of the genetic etiology of pharmacologic sensitivity patterns. Mutant genes in tumors often produce proteins that are not druggable either because of dearth of known agents that interact with the protein or the loss-of-function nature of the genetic event. However, the mutated protein may set off a cascade of intracellular signals that eventually culminates in a druggable protein being involved in the oncogenic process. Genomics can tell us the location of the mutant gene, and functional screens of a variety of formats can identify potentially effective drugs. Both functional and genomic tools can be used in isolation to drive clinical trials and decision-making; however, the intersection of genomic and functional data represents the most promising strategy for accelerated understanding of the mechanistic etiology of drug sensitivity patterns as well as the rapid deployment of gene-targeted therapies for cancer.](TynerMCS001370_F1){#TYNERMCS001370F1}

FUNCTIONAL APPROACHES---STRENGTHS AND LIMITATIONS {#s2}
=================================================

Recent advances in functional screening technology have yielded many variations in assay platforms for understanding responses of tumor cells to exogenous perturbations. Functional screening efforts in hematologic malignancies have often involved the culture of patient cells in conventional two-dimensional tissue culture platforms, sometimes with conventional culture conditions ([@TYNERMCS001370C52], [@TYNERMCS001370C53]; [@TYNERMCS001370C36]) and other times using additives or feeder cell coculture that promote certain phenotypic aspects of the cells, such as preservation of primitive cell differentiation state ([@TYNERMCS001370C33]) and cell proliferation ([@TYNERMCS001370C21]). Although this review focuses mainly on the application of libraries of small molecules to these functional screening platforms, as detailed below this strategy has also been used extensively with RNA interference (RNAi) libraries and more recently with clustered regularly interspersed short palindromic repeat (CRISPR)--Cas technology for mechanistically focused projects.

For solid tumors, two-dimensional culture that retains fidelity to characteristics of the original tumor has proven more challenging and has required the development of a technique called conditional reprogramming, which involves specific media conditions and protocols using feeder cell layers ([@TYNERMCS001370C26]; [@TYNERMCS001370C45]). Analysis of rare circulating tumor cells from solid tumor patients has been another successful avenue for functional screening of solid tumors in two dimensions ([@TYNERMCS001370C6]; [@TYNERMCS001370C57]). In other cases, solid tumor cells have been grown in three-dimensional organoids ([@TYNERMCS001370C41]) or organotypic cultures comprised of multiple cell types rederived into a three-dimensional structure ([@TYNERMCS001370C38]) or live three-dimensional tissue slices ([@TYNERMCS001370C54]), which retain important geographical positioning properties and cell interactions of the original tumor. In many instances, these two- and three-dimensional approaches are used to assess the ability of drugs to halt growth or induce death of tumor cells; however, other approaches use readouts with shorter turnaround time such as target/pathway engagement ([@TYNERMCS001370C42]; [@TYNERMCS001370C16]; [@TYNERMCS001370C47]), activation ([@TYNERMCS001370C17]), or induction of apoptotic responses ([@TYNERMCS001370C32]) as useful surrogates for eventual phenotypic impacts on tumor cells.

In vivo approaches are also commonly explored. Many investigators make use of xenograft animal models for propagation of tumor cells and measurement of the impact of drugs on tumor growth in vivo. In addition, recent approaches have been developed to implant drug libraries into tumors in situ with subsequent resection and imaging to determine each drug\'s impact on the local environment into which the drug was microinjected ([@TYNERMCS001370C19]; [@TYNERMCS001370C22]). A more comprehensive survey and description of the functional screening landscape can be found in [@TYNERMCS001370C11]).

Finally, the recent advances in immunotherapies for oncology have opened the door to functional testing of these agents. Although this is a very new area, investigators are beginning to examine the capacity of immune checkpoint inhibitors to elicit T-cell activation responses when cultured ex vivo in a milieu of tumor cells ([@TYNERMCS001370C24]). It is also conceivable that the ex vivo and in vivo platforms described above could be useful for understanding activity profiles of antibody--drug conjugates or chimeric antigen receptor T cells. Indeed, xenograft models have already been routinely used for validation of in vivo activity of these classes of agents.

Although functional screening is clearly a rapidly expanding field offering many different modalities and opportunities to evaluate candidate drug responses ex vivo and in vivo, there are also some current limitations to these approaches. The start-up costs and expertise to obtain specialized instrumentation and personnel for execution of these screens can be substantial, which may represent an activation barrier for some institutions. In addition, the tissue requirements to perform these screens are often larger than the requirements to perform genomic studies, making the subset of cases for which the technology is not feasible larger for some functional approaches relative to genomics. Finally, although many of the ex vivo approaches, particularly for the hematologic malignancies, can actually deliver data faster than most current genomic facilities, there can be a significant delay in performing the experiments for approaches that require expansion of tumor cells in vivo or ex vivo.

Hence, like the genomic approaches, these functional screening strategies have strengths as well as limitations and the relative strengths and weaknesses of functional and genomic approaches are both ideally suited to complementing the other. As noted above, deep sequencing has revolutionized our ability to efficiently decipher somatic genetic lesions associated with individual patient tumors, yet most are not currently actionable. Functional strategies have the benefit of offering results that can be immediately acted upon in a clinical setting (with proper assay setup and oversight, as noted below); however, the widespread application of findings to patients can be limited without substantial mechanistic exploration. By integrating functional and genomic data sets, it is possible to generate understanding of complex genotype-to-phenotype correlations and, thereby, accelerate discovery of the biology of tumorigenesis as well as the clinical implementation of novel therapies.

CLINICAL IMPLEMENTATION OF FUNCTIONAL OR GENOMIC STRATEGIES {#s3}
===========================================================

Both functional and genomic approaches to personalized medicine face hurdles of implementation, although often for different reasons. Although notable clinical trials incorporate the use of genetic markers for stratification of patients onto specific therapies, these trials are impeded by the paucity of solid hypotheses that enable assignment of specific drugs to specific genetic events. Conversely, functional approaches have the capacity to make predictions of effective therapies for large proportions of patients; however, the validation of these hypotheses in a clinical setting has been impeded by less than widespread acceptance of functional assays for clinical decision-making as well as the other limitations around start-up cost, tissue requirements, and timing noted above. Indeed, the integration of both genomic and functional approaches in a clinical setting holds great promise where patients with immediately targetable genetic lesions could be treated on the basis of genetic findings, whereas functional assays could be used to generate candidate drugs for patients not exhibiting targetable genetic lesions. In general, there are at least three criteria that are important for implementation of these tools in a clinical setting, all of which are relevant to both functional and genomic approaches.

1.  *Precision.* It is vital that any assay or device that is used for clinical decision-making be performed in a stable manner that offers reproducible results. At a minimum, this reproducibility should be validated by internal controls demonstrating consistency of results over time and, ideally, the results should be cross validated with external laboratories performing the same or similar technique. External validation is currently much easier for genomic strategies where nucleic acids can be stably stored for long periods of time and sent to any of a multitude of other laboratories capable of running the same test(s). For functional assays, this manner of external validation has been more difficult because many of these assays require freshly harvested, viable cells and the number of laboratories offering functional tests with regulatory approval has been small. However, in recent years more and more centers and companies have emerged with functional screening capabilities, and even though these tests are not performed in identical manner, it is still becoming possible to orthogonally validate results between platforms at multiple centers.

    Demonstrating the precision and reproducibility of functional testing results is especially important in light of recent analyses of the Cancer Cell Line Encyclopedia ([@TYNERMCS001370C2]) and the Cancer Genome Project ([@TYNERMCS001370C12]) suggesting inconsistent drug sensitivity results between these two collections ([@TYNERMCS001370C14]). Although follow-up analyses showed a higher level of concordance when controlling for genomic variation ([@TYNERMCS001370C48]), the thresholds for precision by which functional screening studies should strive and be evaluated is still a point of discussion ([@TYNERMCS001370C40]). Clearly, for translating these assays into a clinical setting, the highest standards for rigor must be demonstrated.

2.  *Oversight.* As both functional and genomic tools are explored for clinical use in prospective trials, regulatory approval is important. Investigators using such tools for cutting edge trials must consider steps such as certification of assays with the College of American Pathologists and/or the Food and Drug Administration. Putting in place controls as noted above to ensure precision and reproducibility of the assay will be a component of assay oversight as will other common steps such as clear delineation of specimen/protocol tracking and chain of custody. In addition, as new informatics tools are developed that can integrate functional and genomic data (as well as other data sources) to generate informed treatment predictions, these computational tools will also be subject to regulatory oversight at the point of clinical implementation.

3.  *Accuracy*. Although it is clearly important that genomic and functional techniques are performed in a reproducible manner with proper regulatory oversight, it is also clearly desirable that the assay results are reproducibly accurate in predicting clinical responses. This is the most challenging criterion to satisfy, especially as it is somewhat circular in the setting of testing these tools in clinical trials---the point of such trials is to demonstrate assay accuracy. As a result, it will be important that oversight bodies bear in mind that much work remains to be done in demonstrating accuracy and clinical relevance of both functional and genomic tools in reviewing proposed trials that aim to demonstrate assay/biomarker accuracy.

MECHANISTIC INSIGHTS AIDED BY FUNCTIONAL SCREENING {#s4}
==================================================

Even as genomic and functional strategies are being advanced separately for clinical purposes, the research world is already integrating these tools to accelerate discovery. Although there is far too much of this work ongoing for a comprehensive review here, the following represent some examples of functional genomic data integration that has led to novel insights into genotype/phenotype correlations in a few distinct categories.

1.  *Linkage of specific genotype to gene target*. Some of the earliest examples of successfully combining functional with genetic events occurred with the use of RNAi screens ([@TYNERMCS001370C34]; [@TYNERMCS001370C44]), and this work continues with more modern RNAi and/or CRISPR--Cas technologies. Some examples of important findings in this category include the identification of the transcriptional repressor, REST, as a tumor suppressor in colorectal cancer associated with loss-of-function chromosomal deletions or frameshift mutations that lead to increased signaling of progrowth signaling pathways ([@TYNERMCS001370C55]); the ribosomal subunit protein, RPS14, as a critical region of the 5q-deletions observed in myelodysplasia ([@TYNERMCS001370C8]); the cell surface receptor, ROR1, as a functional target in acute lymphoblastic leukemia cases harboring a 1;19 chromosomal translocation ([@TYNERMCS001370C3]); and identification of dependence on several kinase targets such as WEE1 in head and neck squamous cell carcinoma with TP53 mutation ([@TYNERMCS001370C30]). In some instances, these approaches have used primary patient cells to conduct the functional genomic techniques, whereas others have used cell line models ([@TYNERMCS001370C43]).

2.  *Linkage of specific genotype to drug activity/pathway dependence*. Similar to the use of RNAi to elucidate functional gene targets that are associated with specific genetic disease subsets, small-molecule assays have similarly been used to directly identify candidate drugs that may be useful in association with specific genetic markers. Some examples include the use of JAK inhibitors for Philadelphia-negative neutrophilic leukemia cases harboring mutation of CSF3R ([@TYNERMCS001370C28]); the identification of axitinib as a selective inhibitor of BCR-ABL harboring a T315I mutation ([@TYNERMCS001370C37]); and discovery of JAK pathway activation and sensitivity to JAK inhibitors in AML cases with biallelic CEBPA mutations ([@TYNERMCS001370C25]).

3.  *Enrichment of drug efficacy in defined diagnostic subsets*. Although the identification of a genetic marker that mechanistically explains drug sensitivity represents a clear and desirable objective of functional genomics, there are also many findings of functional targets (both targetable and nontargetable with current agents) that associate with broader diagnostic categories. Some examples include identification of the molecular scaffold, CARD11, as an activator of NF-κB signaling in activated B-cell-like diffuse large B-cell lymphoma ([@TYNERMCS001370C31]); activity of BH3 mimetics such as venetoclax for a variety of hematologic malignancy subsets including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia ([@TYNERMCS001370C7]; [@TYNERMCS001370C35]; [@TYNERMCS001370C1]; [@TYNERMCS001370C50]); and distinct activity of BH3 or SMAC mimetics for distinct subsets of acute lymphoblastic leukemia ([@TYNERMCS001370C9]; [@TYNERMCS001370C29]). The predicted clinical activity of some of these agents, such as venetoclax, has been validated in recent clinical trials ([@TYNERMCS001370C39]).

4.  *Understanding drug resistance, predicting effective drug combinations*. Finally, a number of studies have used functional genomic approaches to understand drug resistance, particularly for targeted agents in the setting of specific genetic events. Examples include strategies to tackle resistance to MAP/ERK kinase (MEK)/phosphoinositide 3-kinase (PI3K) inhibitor combinations in lung cancer with RAS mutations ([@TYNERMCS001370C15]); fibroblast growth factor 2 (FGF2) as an autocrine/paracrine mechanism of resistance in gastrointestinal stromal tumors ([@TYNERMCS001370C18]), chronic myeloid leukemia ([@TYNERMCS001370C51]), and RAS mutant solid tumors ([@TYNERMCS001370C27]); resistance to ALK and/or epidermal growth factor receptor (EGFR) inhibitors in lung cancer with fusions or mutations in these genes ([@TYNERMCS001370C56]); and modalities to overcome BRAF inhibitor resistance in melanoma ([@TYNERMCS001370C10]). Finally, although many of these approaches have been carried out using in vitro strategies, there have also been related studies in vivo, such as the identification of strategies to overcome BRAF resistance in melanoma in vivo ([@TYNERMCS001370C20]).

THE PATH FORWARD {#s5}
================

Although tremendous work has already been done and major discoveries have resulted from functional genomics, there is clearly much work still to do. In the research world, it is critical to continue performing these integrated analyses with emerging drugs, combinations of drugs, and technologies such as CRISPR--Cas as well as cutting-edge genomic tools such as single-cell analytics and long-read technology. As technologies evolve and data sets become more complex and larger, it will also be important to refine and develop new computational tools to integrate data sets. Many technologies for this purpose have already been developed involving predictors of functional relevance from sequence/structure data (discussed here in [@TYNERMCS001370C13]), development of large databases of gene/protein interaction networks (e.g., STRING) ([@TYNERMCS001370C46]), and tools to calculate potentially relevant connections between functionally implicated and mutant genes/proteins (e.g., HitWalker) ([@TYNERMCS001370C4], [@TYNERMCS001370C5]). Although this subject is too large to extensively discuss in this commentary, each approach has strengths and limitations; hence, more work is needed to develop best practices for this computational problem.

In the clinical realm, there is a great deal of work that must be done as well. In addition to the steps outlined above for advancing functional and genomic approaches separately, it will also be important to utilize integrated data in a clinical setting. This will require that the computational approaches noted above are designed in a manner that is compatible with patient care. In addition, new computational visualization tools are needed such that these large functional genomic data sets can be rapidly recalled, displayed, and digested for individual patients by clinical personnel working independently and/or working in tandem with researchers in a tumor board-like setting.

In sum, functional genomics has already delivered tremendous insights into the pathogenesis, diagnosis, possible therapeutics, and resistance mechanisms for a wide diversity of cancer subtypes, and new applications of this strategy will continue to impact on cancer research and the deployment of new therapeutic strategies for patients well into the future.
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